Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02401373
Other study ID # GR2015VCT001
Secondary ID
Status Completed
Phase Phase 1
First received March 24, 2015
Last updated July 15, 2015
Start date March 2015
Est. completion date July 2015

Study information

Verified date July 2015
Source First Affiliated Hospital of Zhejiang University
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This is a single center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile, and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged between 18-60 years in China.


Description:

This is a single center, open, dose-escalation clinical trial. According to the Chinese guidelines for vaccine clinical trial, the sample size of a phase 1 clinical trial should be at least 20. In this study, a total of 60 participants will be included.30 participants will be firstly recruited and assigned to receive the low dose Ad5-EBOV. After the safety of the low dose vaccination is confirmed, another 30 participants will be recruited and assigned to receive the high dose Ad5-EBOV.

The whole follow-up period for each participant will be 28 days.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Aged between 18 and 60 years.

- African in China.

- Able to understand the content of informed consent and willing to sign the informed consent

- Able and willing to complete all the secluded study process during the whole study follow-up period (about 1 month).

- A body mass index (BMI) 18.5-35.0 kg/m2

- Hemoglobin =110g/L for female, and =120g/L for male.

- White blood cells (WBC) 4.0-10.0×109 cells/L

- Total lymphocyte Count 0.8-4.5×109 cells/L

- Platelets 100-300×109 cells/L

- Alanine aminotransferase (ALT) 0-40U/L

- Serum creatinine 44-106µmol/L

- Active partial thromboplastin time (APTT) 20-40 seconds

- Prothrombin time (PT) 10-14 seconds

- Negative in HIV diagnostic blood test

- Axillary temperature =37.0°C on the day of enrollment

- General good health as established by medical history and physical examination.

Exclusion Criteria:

- Family history of seizure, epilepsy, brain or mental disease

- Participant that has a medical history of any of the following: allergic history of any vaccination or drugs, or allergic to any ingredient of the Ad5-EBOV, such as mannitol.

- Woman who is pregnant, breast-feeding or positive in ß-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment, or become pregnant during the next 6 months

- Any acute fever disease or infections in last 7 days

- Major congenital defects or not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease

- Hereditary angioneurotic edema or acquired angioneurotic edema

- Urticaria in last one year

- Asplenia or functional asplenia

- Platelet disorder or other bleeding disorder may cause injection contraindication

- Faint at the sight of blood or needles.

- Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months

- Prior administration of blood products in last 4 months

- Prior administration of other research medicines in last 1 month

- Prior administration of attenuated vaccine in last 1 month

- Prior administration of inactivated vaccine in last 14 days

- Current anti-tuberculosis prophylaxis or therapy

- Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Biological:
Ad5-EBOV
intramuscular injection

Locations

Country Name City State
China First affiliated hospital of Zhejiang University Hangzhou Zhejiang

Sponsors (3)

Lead Sponsor Collaborator
First Affiliated Hospital of Zhejiang University Beijing Institute of Bioengineering, Academy of Military Medical Sciences, Tianjin Cansino Biotechnology Inc

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary A Phase I, Open Clinical Trial to Evaluate the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adult Africans in China. From March to July, 2015 Yes
See also
  Status Clinical Trial Phase
Completed NCT00374309 - Experimental Vaccine for Prevention of Ebola Virus Infection Phase 1
Completed NCT03098862 - PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response
Completed NCT02509494 - Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo Phase 3
Recruiting NCT06093646 - Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda N/A
Completed NCT02495246 - A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV Phase 1
Completed NCT04906629 - INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees Phase 1
Completed NCT05064956 - Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study) Phase 2
Not yet recruiting NCT06126822 - Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC Phase 3
Completed NCT02267109 - Phase 1 Trial of Ebola Vaccine in Mali Phase 1
Withdrawn NCT04268966 - An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola Phase 2
Not yet recruiting NCT04822376 - Prophylaxis Vaccine Antibodies Ebola Phase 2
Recruiting NCT02333578 - Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment N/A
Completed NCT02662855 - Efficacy of Favipiravir Against Severe Ebola Virus Disease Phase 2
Active, not recruiting NCT04152486 - Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC Phase 3
Terminated NCT04250168 - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Completed NCT03161366 - Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Phase 3
Completed NCT03140774 - Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines
Suspended NCT03462004 - Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein Phase 1
Active, not recruiting NCT02876328 - Partnership for Research on Ebola VACcinations Phase 2
Not yet recruiting NCT05202288 - Pilot Study Evaluating the Impact of Delay Between Administration of Inmazeb Administration and Vaccination by Ervebo on Vaccine Immune Response on Healthy Volunteers Phase 2